Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice

Kos, Tomasz; Popik, Piotr; Pietraszek, M.; Schäfer, D.; Danysz, Wojciech; Dravolina, Olga A.; Blokhina, Elena; Galankin, T.; Bespalov, Anton

doi:10.1016/j.euroneuro.2005.10.001

Cited by 85 publications

(51 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, several of the tested principles (e.g., 5-HT 2A , 5-HT 3 and 5-HT 6 receptor blockade, ampakines, and NMDA/glycine site stimulation) are known to enhance cognitive function as exemplified by improved performance in delayed matching/nonmatching to sample procedure (Terry et al, 1996(Terry et al, , 2005Hampson et al, 1998;Pussinen and Sirvio, 1999;Meneses, 2001;Kos et al, 2006). This may be viewed as evidence of facilitated working memory and may be beneficial in schizophrenia but did not translate into any meaningful effects in the present study.…”

Section: Discussioncontrasting

confidence: 53%

Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs

Bespalov

Jongen-Rêlo²,

Gaalen³

et al. 2006

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Cortical metabotropic glutamate receptors (mGluRs) seem to be involved in habituation of simple stimulus-bound behaviors (e.g., habituation to acoustic startle or odor-elicited orienting response). Habituation deficits may contribute to the cognitive symptoms of schizophrenia. In the present study, male NMRI mice were injected with mGluR2/3 antagonist 2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid (LY-341495) 30 min before being placed into novel arenas for automatic motor activity recording (2-h sessions). Administration of LY-341495 (1-10 mg/kg s.c.) dose-dependently prevented the habituation of the locomotor activity. Effects of LY-341495 (10 mg/kg) were fully and dose-dependently reversed by i.p. administration of haloperidol (0.03-0.3 mg/kg), clozapine (1-10 mg/kg), risperidone (0.01-0.1 mg/kg), olanzapine (0.3-3 mg/kg), aripiprazole (1-10 mg/kg), and sulpiride (3-30 mg/kg), each of which was given 15 min before the test.Effects of antipsychotic drugs were observed at the dose levels that did not affect spontaneous motor activity. LY-341495-induced delayed hyperactivity was also partially attenuated by lithium (50 -200 mg/kg), amisulpride (1-10 mg/kg), and the selective dopamine D3 antagonist trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011A; 3-30 mg/kg). Application of diazepam, imipramine, or several agonists and/or antagonists acting at various receptors that are thought to be relevant for antipsychotic treatment [e.g., 5-hydroxytryptamine (5-HT) 2A , 5-HT 3 , and 5-HT 6 antagonists; 5-HT 1A agonist; D4 antagonist; CB1 antagonist; ampakines; and glycine transporter inhibitor) had no appreciable effects. Thus, behavioral deficits induced by mGluR2/3 blockade (such as delayed motor hyperactivity) are selectively reversed by clinically used antipsychotic drugs.

show abstract

Section: Discussioncontrasting

confidence: 53%

Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs

Bespalov

Jongen-Rêlo²,

Gaalen³

et al. 2006

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…4,17 Moreover, preclinical studies also demonstrated that ketamine induces anxiolytic-and antidepressant-like effects in rodents subjected to animal models of anxiety and depression. [18][19][20][21] In agreement with these findings, we have also recently demonstrated that acute and chronic administration of ketamine decreased immobility time in the forced swimming test. 22 Correll and Futter observed a mild feeling of "headiness" or inebriation as the only adverse effect of ketamine used in dose well below the anesthetic dose.…”

Section: Introductionsupporting

confidence: 75%

“…21 Chaturvedi et al also demonstrated that ketamine reversed the increase in immobility time induced by shock in the mouse forced swimming test. 19 Finally, Yilmaz et al showed that one single injection of ketamine (160mg/kg, an anesthetic dose) induced antidepressant-like effects in rats tested in 3, 7, or 10 days after the forced swimming test.…”

Section: Discussionmentioning

confidence: 99%

Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats

Assis

Rezin

Comim

et al. 2009

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

“…However, Rammes et al (2001) has demonstrated that neramexane and memantine also inhibit 5-hydroxytryptamine 3 receptor currents in vitro. Because 5-hydroxytryptamine 3 receptor antagonists produce antidepressant-like effects in animal models and also potentiate the antidepressant-like effects of several antidepressants (Martin et al, 1992;Kos et al, 2006), other affected receptor mechanisms cannot be excluded. Pharmacokinetic factors should also be considered when interpreting drug interaction experiments.…”

Section: Discussionmentioning

confidence: 99%

Enhancement of Antidepressant-Like Effects but Not Brain-Derived Neurotrophic Factor mRNA Expression by the Novel N-Methyl-d-aspartate Receptor Antagonist Neramexane in Mice

Kos¹,

Legutko²,

Danysz³

et al. 2006

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Improved efficacy in the treatment of depression may be achieved by the combined use of several antidepressants. In the present study, acute administration of the novel N-methyl-D-aspartate (NMDA) receptor antagonist neramexane, as well as the representative antidepressants imipramine, fluoxetine, and venlafaxine, shortened the duration of immobility in the mouse tail suspension test with a minimal effective dose of 5 mg/kg. When tested in combination, the antidepressant-like effects of 5 mg/kg imipramine, 20 mg/kg fluoxetine, and 5 mg/kg venlafaxine were potentiated by neramexane (2.5 mg/ kg), a dose that alone did not produce a significant effect on the duration of immobility. These effects seemed to be specific, because they were not accompanied by significant effects on locomotor activity. The enhanced antidepressant-like activity produced with the different combinations was not synergistic as determined by comparing the theoretical and observed ED 50 values for each combination. In separate experiments, Northern blot analysis showed that a 14-day treatment with imipramine (10 mg/kg b.i.d.) increased brain-derived neurotrophic factor (BDNF) mRNA expression in the cortex, whereas neramexane (5 mg/kg b.i.d.) decreased it. Combined treatment produced no effect on BDNF mRNA expression. Mice treated with imipramine or neramexane for 14 days and tested shortly after the last dose demonstrated significant shortening of immobility, and the combined treatment produced an even greater antidepressant-like effect. Together, these data support the view that NMDA receptor antagonists enhance the potency of antidepressants, but they leave open the question as to whether enhanced BDNF expression is a necessary feature of the antidepressant-like effect.

show abstract

Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice

Cited by 85 publications

References 42 publications

Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs

Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs

Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats

Enhancement of Antidepressant-Like Effects but Not Brain-Derived Neurotrophic Factor mRNA Expression by the Novel N-Methyl-d-aspartate Receptor Antagonist Neramexane in Mice

Contact Info

Product

Resources

About